RESUMO
AIM: This study investigates the relationship between posture disorders and swallowing, either of infantile type or affected by the presence of a short lingual frenulum. MATERIALS AND METHODS: The stabilometry examinations, taking into account the Romberg index and the LFS value, and when needed a frenectomy, showed positive variations in the recovery of a proper posture. The data were analysed by means of the Wilcoxon signed-rank test. RESULTS AND CONCLUSION: This study showed that swallowing is able to modulate postural control and it can be a determining factor in postural syndromes that, if not promptly intercepted, may evolve into full-blown and irreversible musculoskeletal disorders for which treatment often proves ineffective.
Assuntos
Deglutição/fisiologia , Postura/fisiologia , Criança , Transtornos de Deglutição/fisiopatologia , Transtornos de Deglutição/terapia , Movimentos Oculares/fisiologia , Feminino , Humanos , Freio Lingual/anormalidades , Freio Lingual/cirurgia , Masculino , Mordida Aberta/fisiopatologia , Mordida Aberta/terapia , Equilíbrio Postural/fisiologia , Língua/anormalidades , Língua/fisiopatologia , Hábitos Linguais/efeitos adversos , Hábitos Linguais/terapia , Visão Ocular/fisiologiaRESUMO
BACKGROUND/AIM: Data on management and long-term follow-up of Helicobacter pylori-associated MALT-lymphoma in clinical practice are scanty. We evaluate the long-term efficacy of H. pylori eradication on low-grade MALT-lymphoma, and the efficacy of further therapies in refractory patients. METHODS: This study enrolled patients with stages I-II(1) MALT-lymphoma and H. pylori infection. H. pylori eradication was attempted in all patients. Patients with lymphoma persistence or progression following H. pylori treatments received further lymphoma treatments. Both 5-year and disease-free survivals were calculated. RESULTS: Sixty patients (stage I/II(1): 50/10) were followed up for a median time of 65 months (range 7-156). H. pylori infection was successfully eradicated in 53 (88.3%) patients following three consecutive therapeutic attempts, and lymphoma regressed in 42 (79.2%) of these patients. Sixteen patients received anti-neoplastic treatments due to either lymphoma persistence or progression, and lymphoma was cured in 14 (87.5%) cases. At follow-up, lymphoma relapsed in 13/42 (30.9%) patients within a median time of 19 months (range 3-41), and all but 1 patient were cured with further therapies. Overall, lymphoma regression was achieved in 56 patients (93.3%). The 5-year and disease-free survivals were 94.7% and 74.6%, respectively. CONCLUSIONS: In clinical practice, a conservative approach with antibiotic eradication seems to be appropriate management for early-stage MALT-lymphoma, with oncologic therapy being reserved for those patients who fail to respond to H. pylori therapy.